Literature DB >> 19168518

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

Ramón Martos1, John Baugh, Mark Ledwidge, Christina O'Loughlin, Niamh F Murphy, Carmel Conlon, Anil Patle, Seamas C Donnelly, Kenneth McDonald.   

Abstract

AIMS: Heart failure with preserved ejection fraction (HF-PEF) can be difficult to diagnose in clinical practice. Myocardial fibrosis is a major determinant of diastolic dysfunction (DD), potentially contributing to the progression of HF-PEF. The aim of this study was to analyse whether serological markers of collagen turnover may predict HF-PEF and DD. METHODS AND
RESULTS: We included 85 Caucasian treated hypertensive patients (DD n=65; both DD and HF-PEF n=32). Serum carboxy (PICP), amino (PINP), and carboxytelo (CITP) peptides of procollagen type I, amino (PIIINP) peptide of procollagen type III, matrix metalloproteinases (MMP-1, MMP-2, and MMP-9), and tissue inhibitor of MMP levels were assayed. Using receiver operating characteristic curve analysis, MMP-2 (AUC=0.91; 95% CI: 0.84, 0.98), CITP (0.83; 0.72, 0.92), PICP (0.82; 0.72, 0.92), B-type natriuretic peptide (BNP) (0.82; 0.73, 0.91), MMP-9 (0.79; 0.68, 0.89), and PIIINP (0.78; 0.66, 0.89) levels were significant predictors of HF-PEF (P<0.01 for all). Carboxytelo peptides of procollagen type I (AUC=0.74; 95% CI: 0.62, 0.86), MMP-2 (0.73; 0.62, 0.84), PIIINP (0.73; 0.60, 0.85), BNP (0.69; 0.55, 0.83) and PICP (0.66; 0.54, 0.78) levels were significant predictors of DD (P<0.05 for all). A cutoff of 1585 ng/mL for MMP-2 provided 91% sensitivity and 76% specificity for predicting HF-PEF and combinations of biomarkers could be used to adjust either sensitivity or specificity.
CONCLUSION: Markers of collagen turnover identify patients with HF-PEF and DD. Matrix metalloproteinase 2 may be more useful than BNP in the identification of HF-PEF. This suggests that these new biochemical tools may assist in identifying patients with these diagnostically challenging conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168518      PMCID: PMC2639413          DOI: 10.1093/eurjhf/hfn036

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  26 in total

Review 1.  Clinical practice. Diastolic heart failure.

Authors:  Gerard P Aurigemma; William H Gaasch
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Authors:  Emily Lubien; Anthony DeMaria; Padma Krishnaswamy; Paul Clopton; Jen Koon; Radmila Kazanegra; Nancy Gardetto; Erin Wanner; Alan S Maisel
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

3.  Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.

Authors:  Javier Díez; Ramón Querejeta; Begoña López; Arantxa González; Mariano Larman; José L Martínez Ubago
Journal:  Circulation       Date:  2002-05-28       Impact factor: 29.690

4.  Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart.

Authors:  Y Ogawa; N Tamura; H Chusho; K Nakao
Journal:  Can J Physiol Pharmacol       Date:  2001-08       Impact factor: 2.273

5.  Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes.

Authors:  Teruhiko Ito; Michihiro Yoshimura; Shota Nakamura; Masafumi Nakayama; Yukio Shimasaki; Eisaku Harada; Yuji Mizuno; Megumi Yamamuro; Masaki Harada; Yoshihiko Saito; Kazuwa Nakao; Hiroki Kurihara; Hirofumi Yasue; Hisao Ogawa
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

6.  Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction?

Authors:  M C Petrie; K Hogg; L Caruana; J J V McMurray
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 7.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Authors:  Karen Hogg; Karl Swedberg; John McMurray
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

8.  Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy.

Authors:  Hitoshi Yamaguchi; Junichi Yoshida; Kazuhiro Yamamoto; Yasushi Sakata; Toshiaki Mano; Noriyuki Akehi; Masatsugu Hori; Young-Jae Lim; Masayoshi Mishima; Tohru Masuyama
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

9.  Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters.

Authors:  Hisham Dokainish; William A Zoghbi; Nasser M Lakkis; Faiz Al-Bakshy; Meeney Dhir; Miguel A Quinones; Sherif F Nagueh
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Myocardial collagen turnover in hypertrophic cardiomyopathy.

Authors:  Raffaella Lombardi; Sandro Betocchi; Maria Angela Losi; Carlo Gabriele Tocchetti; Mariano Aversa; Marianna Miranda; Gianluigi D'Alessandro; Alessandra Cacace; Quirino Ciampi; Massimo Chiariello
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more
  51 in total

Review 1.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

3.  Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.

Authors:  Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2011-02-24       Impact factor: 8.790

Review 4.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

5.  Pressure overload induces early morphological changes in the heart.

Authors:  Colby A Souders; Thomas K Borg; Indroneal Banerjee; Troy A Baudino
Journal:  Am J Pathol       Date:  2012-09-04       Impact factor: 4.307

Review 6.  Cardiac aging and heart disease in humans.

Authors:  Marja Steenman; Gilles Lande
Journal:  Biophys Rev       Date:  2017-03-20

Review 7.  Biochemical markers of aging for longitudinal studies in humans.

Authors:  Peter M Engelfriet; Eugène H J M Jansen; H Susan J Picavet; Martijn E T Dollé
Journal:  Epidemiol Rev       Date:  2013-02-04       Impact factor: 6.222

8.  The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.

Authors:  Raoul Stahrenberg; Frank Edelmann; Meinhard Mende; Anke Kockskämper; Hans-Dirk Düngen; Claus Lüers; Lutz Binder; Christoph Herrmann-Lingen; Götz Gelbrich; Gerd Hasenfuss; Burkert Pieske; Rolf Wachter
Journal:  Eur J Heart Fail       Date:  2010-09-13       Impact factor: 15.534

Review 9.  Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

Authors:  Michael R Zile; Catalin F Baicu
Journal:  J Cardiovasc Transl Res       Date:  2013-05-29       Impact factor: 4.132

Review 10.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.